OCGN: Ocugen Inc. Stocks News on July 1, 2025

Carisma Therapeutics, OrthoCellix enter definitive merger agreement

OCGN

TipRanks

7 days ago

Carisma Therapeutics, OrthoCellix enter definitive merger agreement

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

OCGN

GlobeNewswire

8 days ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment

OCGN

Clinical Trials Arena

14 days ago

FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment

OCGN

MT Newswires

15 days ago

Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

OCGN

GlobeNewswire

15 days ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

OCGN

GlobeNewswire

20 days ago

Ocugen To Present at BIO International Convention 2025

OCGN

MT Newswires

a month ago

Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

OCGN

GlobeNewswire

a month ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

OCGN

MT Newswires

a month ago

Ocugen Gets FDA Rare Pediatric Disease Label for OCU410ST

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

OCGN

GlobeNewswire

a month ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Exploring 3 High Growth Tech Stocks In The US Market

OCGN

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In The US Market

OCGN

GuruFocus.com

2 months ago

Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ...

OCGN

Associated Press Finance

2 months ago

Ocugen: Q1 Earnings Snapshot

Ocugen Provides Business Update with First Quarter 2025 Financial Results

OCGN

GlobeNewswire

2 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

OCGN

GlobeNewswire

2 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

OCGN

GlobeNewswire

2 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

OCGN

Insider Monkey

2 months ago

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

OCGN

GlobeNewswire

3 months ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

OCGN

Zacks

3 months ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200

OCGN

Clinical Trials Arena

3 months ago

Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200

OCGN

MT Newswires

3 months ago

Ocugen Advances OCU200 Trial After Safety Board Review

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

OCGN

GlobeNewswire

3 months ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

OCGN

MT Newswires

4 months ago

Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating

Ocugen Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

OCGN

Simply Wall St.

4 months ago

Ocugen Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

OCGN

GuruFocus.com

4 months ago

Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs

OCGN

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Ocugen Inc Earnings Call

OCGN

Motley Fool

4 months ago

Ocugen (OCGN) Q4 2024 Earnings Call Transcript

OCGN

Associated Press Finance

4 months ago

Ocugen: Q4 Earnings Snapshot

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

OCGN

GlobeNewswire

4 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

OCGN

MT Newswires

4 months ago

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

OCGN

GlobeNewswire

4 months ago

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

OCGN

GlobeNewswire

4 months ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

OCGN

GlobeNewswire

4 months ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

OCGN

Insider Monkey

5 months ago

Why Ocugen (OCGN) Is Advancing Today

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCGN

GlobeNewswire

5 months ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCGN

MT Newswires

5 months ago

Ocugen Says EMA Panel Issues Positive Opinion for Potential Eye Disease Treatment

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

OCGN

GlobeNewswire

5 months ago

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

OCGN

MT Newswires

5 months ago

Ocugen Files Secondary Stock Shelf

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

OCGN

GlobeNewswire

5 months ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment

OCGN

Clinical Trials Arena

5 months ago

Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment

OCGN

MT Newswires

5 months ago

Ocugen Reports Dosing of First Patient in Diabetic Macular Edema Trial

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

OCGN

GlobeNewswire

5 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

OCGN

MT Newswires

6 months ago

Ocugen Says Potential Retinitis Pigmentosa Therapy Improves Visual Acuity in Phase 1/2 Trial

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

OCGN

GlobeNewswire

6 months ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

5 Biotech Breakthrough Stocks to Watch in 2025

OCGN

Zacks

6 months ago

5 Biotech Breakthrough Stocks to Watch in 2025

OCGN

MT Newswires

6 months ago

Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCGN

GlobeNewswire

6 months ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

OCGN

GlobeNewswire

7 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

OCGN

GlobeNewswire

7 months ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

OCGN

MT Newswires

7 months ago

Ocugen's Eye Disease Treatment Receives Orphan Drug Designation in Europe for Retinopathies

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

OCGN

GlobeNewswire

7 months ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCGN

GlobeNewswire

7 months ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCGN

Zacks

8 months ago

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

OCGN

Associated Press Finance

8 months ago

Ocugen: Q3 Earnings Snapshot

OCGN

Thomson Reuters StreetEvents

8 months ago

Q3 2024 Ocugen Inc Earnings Call

OCGN

GuruFocus.com

8 months ago

Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

OCGN

Motley Fool

8 months ago

Ocugen (OCGN) Q3 2024 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

OCGN

GlobeNewswire

8 months ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen Secures $30 Million in Debt Funding

OCGN

GlobeNewswire

8 months ago

Ocugen Secures $30 Million in Debt Funding

OCGN

Simply Wall St.

8 months ago

Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

OCGN

GlobeNewswire

8 months ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

OCGN

MT Newswires

8 months ago

Ocugen Receives Approval to Begin Dosing in Phase 2 Trial of CU410ST to Treat Genetic Eye Disease

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

OCGN

GlobeNewswire

8 months ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

OCGN

GlobeNewswire

8 months ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

State Street Corp's Strategic Acquisition of Shares in Ocugen Inc

OCGN

GuruFocus.com

8 months ago

State Street Corp's Strategic Acquisition of Shares in Ocugen Inc

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

OCGN

GlobeNewswire

9 months ago

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

OCGN

GuruFocus.com

9 months ago

Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

OCGN

MT Newswires

9 months ago

Ocugen Says FDA Lifts Clinical Hold for Diabetic Macular Edema Treatment Study

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

OCGN

GlobeNewswire

9 months ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

OCGN

GlobeNewswire

9 months ago

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

OCGN

GlobeNewswire

9 months ago

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

OCGN

GlobeNewswire

10 months ago

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

OCGN

GlobeNewswire

10 months ago

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

OCGN

GlobeNewswire

10 months ago

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

OCGN

MT Newswires

10 months ago

Sector Update: Health Care Stocks Steady Premarket Wednesday

OCGN

MT Newswires

10 months ago

Ocugen Completes Dosing in Third Cohort in Trial of Stargardt Disease Treatment

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

OCGN

GlobeNewswire

10 months ago

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up

OCGN

Zacks

10 months ago

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up

OCGN

MT Newswires

10 months ago

Ocugen Says Health Canada Clears OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

OCGN

GlobeNewswire

10 months ago

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

OCGN

Thomson Reuters StreetEvents

a year ago

Q2 2024 Ocugen Inc Earnings Call

OCGN

Motley Fool

a year ago

Ocugen (OCGN) Q2 2024 Earnings Call Transcript

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

OCGN

GlobeNewswire

a year ago

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

OCGN

Associated Press Finance

a year ago

Ocugen: Q2 Earnings Snapshot

OCGN

MT Newswires

a year ago

Ocugen Gets Expanded Access Program Approval for OCU400 From FDA

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

OCGN

GlobeNewswire

a year ago

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

OCGN

MT Newswires

a year ago

Ocugen Closes $35 Million Common Stock Offering

OCGN

MT Newswires

a year ago

Ocugen Prices $35 Million Common Stock Offering

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

OCGN

GlobeNewswire

a year ago

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

OCGN

GlobeNewswire

a year ago

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

OCGN

GlobeNewswire

a year ago

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

OCGN

GlobeNewswire

a year ago

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

OCGN

Motley Fool

a year ago

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

OCGN

Zacks

a year ago

Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?

OCGN

MT Newswires

a year ago

Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

OCGN

GlobeNewswire

a year ago

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

OCGN

GlobeNewswire

a year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

OCGN

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

OCGN

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

OCGN

GlobeNewswire

a year ago

Latest Ocugen Inc. (OCGN) News on July 1, 2025

Share on Social Networks: